Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) said a clinical trial carried out by its subsidiary KGK Science has demonstrated evidence that UP360 supplementation supports a robust immune response in healthy adults following influenza vaccination.
UP360, developed by Unigen, contains aloe vera gel and Poria cocos mushroom and rosemary extracts to produce antioxidant, anti-inflammatory, and immunomodulatory effects, according to Wellbeing.
KGK’s randomized, triple-blind, placebo-controlled clinical trial is the first to examine a proprietary combination of these ingredients using a human vaccine model.
Wellbeing said that the results, published in Frontiers in Nutrition, showed that supplementation with UP360 post-vaccine increased the percentage of TCR gamma-delta cells, known to provide a first line of immune defense for mucosal membranes, in the post-vaccination period when compared to the placebo.
It also increased blood levels of antioxidative stress biomarker glutathione peroxidase and influenza B-specific IgG antibodies before and after the vaccination respectively, the company highlighted.
“UP360 supplementation provided a beneficial immune defense response and improved antioxidant function in conjunction with traditional vaccination, adopted by many as part of their overall immune health strategy,” says KGK chief scientific affairs and regulatory officer Corey Hilmas in a statement.
“Using a vaccine model offered a unique strategy to evaluate the effect of UP360 oral administration on the immune response.”
The company noted that, before expanding the specific application of UP360 ingredients, further research is warranted to better understand efficacy among populations at greater risk of upper respiratory tract infections and the effect on other clinically relevant immune cell populations.
Unigen discovers, develops, and manufactures proprietary natural-product active ingredients for dietary supplements, cosmetic and personal care products, prescription medical food and botanical drug products.
A subsidiary of Wellbeing, KGK is a leading North American contract research organization based in London, Ontario that primarily provides high-quality clinical research trials with a focus on nutraceutical and emerging healthcare products.
Wellbeing is an evidence-based mental healthcare company focused on the development and implementation of innovative clinical treatment solutions, including psychedelic medicine and digital therapeutics, as supported by clinical research.
Contact the author at emily.jarvie@proactiveinvestors.com
Follow her on Twitter @emilyjjarvie